Piriteze Allergy Tablets
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Piriteze Allergy Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
10 mg of cetirizine hydrochloride For excipients, see 6.1.
3. PHARMACEUTICAL FORM
Film coated tablets.
White to off white capsule-shaped tablet, debossed with C10 on one side and a deep breakline on the other.
4. CLINICAL PARTICULARS
4.1. Therapeutic indications
In adults and paediatric patients 6 years and above:
- Cetirizine is indicated for the relief of nasal and ocular symptoms of seasonal and perennial allergic rhinitis.
- Cetirizine is indicated for the relief of symptoms of chronic idiopathic urticaria.
4.2 Posology and method of administration
Children aged from 6 to 12 years: 5mg twice daily (a half tablet twice daily).
Adults and adolescents over 12 years if age: 10 mg once daily (1 tablet once daily).
Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function is normal.
Patients with moderate to severe renal impairment: there are no data to document the efficacy/safety ratio in patients with renal impairment. Since cetirizine is mainly excreted via renal route (see section 5.2), in cases no alternative treatment can be used, the dosing intervals must be individualised according to renal function. Refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient’s creatinine clearance (CLcr) in ml/min is needed. The CLcr ml/min may be estimated from serum creatinine (mg/dl) determination using the following formula:
CLcr = [140 - age(years)! x weight (kg) (x 0.85 for Woman)
72 x serum creatinine (mg/dl)
Dosing Adjustments for Adult Patients with Impaired Renal Function
|
Group |
Creatinine clearance (ml/min) |
Dosage and frequency |
|
Normal |
> 80 |
10 mg once daily |
|
Mild |
50-79 |
10 mg once daily |
|
Moderate |
30-49 |
5 mg once daily |
|
Severe |
< 30 |
5 mg once every 2 days |
|
End-stage renal disease -Patients undergoing dialysis |
< 10 |
Contra-indicated |
In paediatric patients suffering from renal impairment, the dose will have to be adjusted on an individual basis taking into account the renal clearance of the patient, their age and body weight.
Patients with hepatic impairment: no dose adjustment is needed in patients with solely hepatic impairment.
Patients with hepatic impairment and renal impairment: dose adjustment is recommended (see Patients with moderate to severe renal impairment above).
4.3 Contraindications
Hypersensitivity to the active substance, to any of the excipients, to hydroxyzine or to any piperazine derivatives.
Patients with severe renal impairment at less than 10 ml/min creatinine clearance.
4.4 Special warning and precautions for use
At therapeutic doses, no clinically significant interactions have been demonstrated with alcohol (for a blood alcohol level of 0.5 g/l). Nevertheless, precaution is recommended if alcohol is taken concomitantly.
Caution should be taken in patients with predisposition factors of urinary retention (e.g. spinal cord lesion, prostatic hyperplasia) as cetirizine may increase the risk of urinary retention.
Caution in epileptic patients and patients at risk of convulsions is recommended.
The use of the film-coated tablet formulation is not recommended in children aged less than 6 years since this formulation does not allow for appropriate dose adaptation.
Allergy skin tests are inhibited by antihistamines and a wash-out period (of 3 days) is required before performing them.
This product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency of glucose-galactose malabsorption should not take cetirizine film-coated tablets.
4.5. Interaction with other medicinal products and other forms of interaction
Due to pharmacokinetic, pharmacodynamic and tolerance profile of cetirizine, no interactions are expected with this antihistamine. Actually, neither pharmacodynamic nor significant pharmacokinetic interaction was reported in drug-drug interactions studies perfomed, notably with pseudoephedrine or theophylline (400 mg/day).
The extent of absorption of cetirizine is not reduced with food, although the rate of absorption is decreased.
4.6 Pregnancy and lactation
Data on a limited number of exposed pregnancies indicate no adverse effects of cetirizine on pregnancy or on health of foetus/new born child. To date no other relevant epidemiological data are available.
Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or post-natal development (see5.3). Caution should be exercised when prescribing to pregnant women.
Breast feeding.
Caution should be exercised when prescribing cetirizine to lactating women.
Cetirizine is excreted in human milk at concentrations representing 25% to 90% of those measured in plasma, depending on sampling time after administration.
4.7 Effects on ability to drive and use machines
Studies in healthy volunteers at 20 and 25mg/day have not revealed adverse effects on alertness or reaction time. However, patients are advised not to exceed the recommended dose if driving or operating machinery even though cetirizine has no or negligible influence on these parameters.
In sensitive patients, concurrent use with alcohol or other CNS depressants may cause additional reductions in alertness and impairment of performance.
4.8. Undesirable effects
Clinical studies have shown that cetirizine at the recommended dosage has minor undesirable effects on the CNS, including somnolence, fatigue, dizziness and headache. In some cases,
paradoxical CNS stimulation has been reported.
Although cetirizine is a selective antagonist of peripheral H1-receptors and is relatively free of antichloinergic activity, isolated cases of micturition difficulty, eye accommodation disorders and dry mouth have been reported.
Instances of abnormal hepatic function with elevated hepatic enzymes accompanied by elevated bilirubin have been reported. Mostly this resolves upon discontinuation of the treatment with cetirizine hydrochloride.
Clinical trails
Double blind controlled clinical or pharmacoclinical trials comparing cetirizine to placebo or other antihistamines at the recommended dosage (10 mg daily for cetirizine), of which quantified safety data are available, included more than 3200 subjects exposed to cetirizine.
From this pooling, the following adverse events were reported for cetirizine 10 mg in the placebo-controlled trials at rates of 1.0% or greater:
|
Adverse event (WHO-ART) |
Cetirizine 10 mg (n=3260) |
Placebo (n=3061) |
|
Body as a whole - general disorders Fatigue |
1.63% |
0.95% |
|
Central and peripheral nervous system disorders Dizziness |
1.10% |
0.98% |
|
Headache |
7.42% |
8.07% |
|
Gastro-intestinal system |
|
disorders Abdominal pain Dry mouth Nausea |
0.98% 2.09% 1.07% |
1.08% 0.82% 1.14% |
|
Psychiatric disorders Somnolence |
9.63% |
5.00% |
|
Respiratory system disorders Pharyngitis |
1.29% |
1.34% |
Although statistically more common than under placebo, somnolence was mild to moderate in the majority of cases. Objective tests as demonstrated by other studies have demonstrated that usual daily activities are unaffected at the recommended daily dose in healthy young volunteers.
Adverse drug reactions at rates of 1 % or greater in children aged from 6 months to 12 years, included in placebo-controlled clinical or pharmacoclinical trials are:
|
Adverse event (WHO-ART) |
Cetirizine 10 mg (n=1656) |
Placebo (n=1294) |
|
Gastro-intestinal system disorders Diarrhoea |
1.0% |
0.6% |
|
Psychiatric disorders Somnolence |
1.8% |
1.4% |
|
Respiratory system disorders Rhinitis |
1.4% |
1.1% |
|
Body as a whole - general disorders Fatigue |
1.0% |
0.3% |
Post-marketing experience
In addition to the adverse effects reported during clinical studies and listed above, isolated cases of the following adverse drug reactions have been reported in post-marketing experience. For the less frequently reported undesirable effects, the estimated frequencies (uncommon: □ 1/1,000 to 1/100, rare: □ 1/10,000 to 1/1,000, very rare: 1/10,000) are made based on postmarketing experience.
Blood and lymphatic disorders:
Very rare: thrombocytopenia Immune system disorders:
Rare: hypersensitivity Very rare: anaphylactic shock
Metabolism and nutrition disorders:
Not known: increased appetite
Psychiatric disorders:
Uncommon: agitation
Rare: aggression, confusion, depression, hallucinations, insomnia Very rare: tic
Not known: suicidal ideation
Nervous system disorders:
Uncommon: paraesthesia
Rare: convulsions, movement disorders
Very rare; dysgeusia, syncope, tremor, dystonia, dyskinesia
Unknown: amnesia, memory impairment
Eye disorders:
Very rare: accommodation disorder, blurred vision, oculogyration
Ear and labyrinth disorders:
Not known: vertigo
Cardiac disorders:
Rare: tachycardia
Gastro-intestinal disorders:
Uncommon: diarrhoea
Hepatobiliary disorders:
Rare: hepatic function abnormal (increased transaminases, alkaline phosphataes, y-GT and bilirubin)
Skin and subcutaneous tissue disorders:
Uncommon: pruritus, rash Rare: urticaria
Very rare: angioneurotic oedema, fixed drug eruption
Renal and urinary disorders:
Very rare: dysuria, enuresis
Not known: urinary retention (see section Warnings and Precautions)
General disorders and administration site conditions:
Uncommon: asthenia, malaise Rare: oedema
Investigations:
Rare: weight increased
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at:www.mhra.gov.uk/yellowcard.
4.9 Overdose
Toxicity: There is limited experience of overdosing. 20 mg to a 2 year old, 30 mg to a 3 year old and 40 mg to an 11 year old did not give any symptoms. 60 mg to a 4 year old gave mild intoxication, 400 mg to a 14 year old gave mild symptoms while 400-500 mg to an adult gave no symptoms at all.
a) Symptoms
Symptoms observed after an overdose of cetirizine are mainly associated with CNS effects or with effects that could suggest an anticholinergic effect. Adverse events reported after an intake of at least 5 times the recommended daily dose are: confusion, diarrhoea, dizziness, fatigue, headache, malaise, mydriasis, pruritus, restlessness, sedation, somnolence, stupor, tachycardia, tremor, and urinary retention.
b) Management
There is no known specific antidote to cetirizine.
Should overdose occur, symptomatic or supportive treatment is recommended. Cetirizine is not effectively removed by dialysis.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Piperazine derivatives, ATC code: R06A E07
Cetirizine, a human metabolite of hydroxyzine, is a potent and selective antagonist of peripheral H1-receptors. In vitro receptor binding studies have shown no measurable affinity for receptors other than H1-receptors.
In addition to its anti-H1 effect, cetirizine was shown to display anti-allergic activities: at a dose of 10 mg once or twice daily, it inhibits the late phase recruitment of eosinophils, in the skin and conjuctivia of atopic subjects submitted to allergen challenge.
Studies in healthy volunteers show that cetirizine, at doses of 5 and 10 mg strongly inhibits the wheal and glare reactions induced by very high concentrations of histamine into the skin, but the correlation with efficacy is not established.
In a 35-day study in children aged 5 to 12, no tolerance to the antihistamine effect (suppression of wheal and flare) of cetirizine was found. When a treatment with cetirizine is stopped after repeated administration, the skin recovers its normal reactivity to histamine within 3 days.
In a six-week, placebo-controlled study of 186 patients with allergic rhinitis and concomitant mild to moderate asthma, cetirizine 10 mg once daily improved rhinitis symptoms and did not alter pulmonary function. This study supports the safety of administering cetirizine to allergic patients with mild to moderate asthma.
In a placebo-controlled study, cetirizine give at the high daily dose of 60 mg for seven days did not cause statistically significant prolongation of QT interval.
At the recommended dosage, cetirizine has demonstrated that it improves the quality of life of patients with perennial and seasonal allergic rhinitis.
5.2 Pharmacokinetic properties
Peak blood levels in the order of 0.3pg/ml are reached within about one hour after the oral administration of cetirizine. The terminal half-life is approximately ten hours in adults and six hours in children aged 6 - 12 years.
This is consistent with the urinary excretion half-life of the drug. The cumulative urinary excretion represents about two thirds of the dose given for both adults and children.
Consequently, the apparent plasma clearance in children is higher than that measured in adults. Plasma levels are linearly related to the dose given. A high proportion of cetirizine is bound to human plasma proteins.
5.3 Preclinical safety data
Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction.
Preclinical results were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Tablet core:
Microcrystalline cellulose Lactose monohydrate Colloidal anhydrous silica Magnesium stearate
Coating:
Hypromellose (E464)
Macrogol 4000 Titanium dioxide (E171)
Polydextrose
6.2 Incompatibilities
Not applicable
6.3 Shelf life
36 months
6.4 Special precautions for storage
No special precautions for storage
6.5. Nature and contents of container
Transparent or white opaque PVC/PVdC - aluminium blister packs containing 4, 7, 12, 14 or 30 film-coated tablets.
6.6 Special precautions for disposal
Not applicable
7 MARKETING AUTHORISATION HOLDER
Beecham Group PLC
Trading as GlaxoSmithKline Consumer Healthcare
980 Great West Road
Brentford
Middlesex
TW8 9GS
United Kingdom
8 MARKETING AUTHORISATION NUMBER
PL 00079/0398
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
25 September 2003 / 13 March 2009
10 DATE OF REVISION OF THE TEXT
11/11/2014